Anaplastic Large Cell Lymphoma Active Not Recruiting Phase 1 Trials for DB05220 (Alisertib)

Also known as: Lymphomas, Anaplastic Large-Cell / Anaplastic large-cell lymphoma / Large cell (Ki-1+) lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large cell lymphoma, CD30-positive

IndicationStatusPhase
DBCOND0028602 (Anaplastic Large Cell Lymphoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01567709Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaTreatment